Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAC-containing vs Preservative-free Albuterol in Status Asthmaticus
NCT02966184Phase 4Terminated
- Sponsor
- Norton Healthcare
- Start
- Sep 2018
- Primary completion
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of salbutamol in status asthmaticus (2 arms), sponsored by Norton Healthcare. Primary endpoint: Length of continuous albuterol administration up to 72 hours. Started Sep 2018; status: terminated.
02
Drugs
salbutamol
03
Conditions
status asthmaticus
Beyond the preview
Go deeper on NCT02966184.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02966184.